CVS Health (NYSE:CVS) Given New $107.00 Price Target at Barclays

CVS Health (NYSE:CVS) had its price target trimmed by Barclays from $108.00 to $107.00 in a report published on Thursday,Benzinga reports. The firm currently has an overweight rating on the pharmacy operator’s stock.

Other analysts have also recently issued research reports about the stock. Robert W. Baird set a $107.00 price target on shares of CVS Health in a research report on Thursday, August 6th. Raymond James Financial restated an “outperform” rating and issued a $120.00 price objective on shares of CVS Health in a report on Wednesday. BMO Capital Markets set a $112.00 target price on shares of CVS Health in a research note on Wednesday, September 9th. Wall Street Zen downgraded shares of CVS Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 19th. Finally, Wells Fargo & Company increased their target price on shares of CVS Health from $103.00 to $123.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Twenty-two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $109.08.

CVS Health Trading Up 1.6%

Shares of NYSE CVS opened at $81.22 on Thursday. The stock has a fifty day simple moving average of $90.56 and a 200-day simple moving average of $88.87. CVS Health has a twelve month low of $69.51 and a twelve month high of $110.68. The company has a current ratio of 0.85, a quick ratio of 0.66 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $103.88 billion, a PE ratio of 9.46, a PEG ratio of 0.73 and a beta of 0.58.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.65 by $0.44. The company had revenue of $108.40 billion during the quarter, compared to analysts’ expectations of $104.72 billion. CVS Health had a return on equity of 13.65% and a net margin of 2.62%. CVS Health’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the business posted $1.60 EPS. On average, equities analysts forecast that CVS Health will post 8.20 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Thursday, October 22nd were paid a dividend of $0.6650 per share. The ex-dividend date was Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.3%. CVS Health’s payout ratio is presently 30.97%.

Institutional Trading of CVS Health

A number of hedge funds and other institutional investors have recently bought and sold shares of CVS. Handelsbanken Fonder AB boosted its stake in shares of CVS Health by 83.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 1,089,694 shares of the pharmacy operator’s stock valued at $112,729,000 after buying an additional 496,124 shares during the last quarter. BNP Paribas grew its position in shares of CVS Health by 105.2% during the 2nd quarter. BNP Paribas now owns 49,971 shares of the pharmacy operator’s stock valued at $5,154,000 after buying an additional 25,617 shares during the last quarter. Nykredit A S acquired a new stake in shares of CVS Health during the 2nd quarter worth approximately $209,813,000. Oppenheimer Asset Management Inc. bought a new stake in CVS Health in the second quarter valued at $49,622,000. Finally, Bank of America Corp DE lifted its position in CVS Health by 148.0% in the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock valued at $2,398,868,000 after purchasing an additional 13,836,701 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported adjusted third-quarter earnings of $2.09 per share, above the $1.65 consensus, while revenue rose 5.4% year over year to $108.4 billion. Management also raised its 2026 adjusted EPS outlook to at least $8.20 and operating cash-flow outlook to at least $15.5 billion. These results and stronger performance in benefits and pharmacy are supportive of the investment case. CVS Health reports third-quarter results and raises guidance
• Neutral Sentiment: The company plans to separate its retail pharmacies from its insurance and pharmacy-benefit operations by the first half of 2028. CVS says the two businesses could have more focused strategies; shareholders are expected to own both companies. But the timeline leaves time for execution risks, and details of the separation remain important. CVS plans to split itself up
• Negative Sentiment: The breakup announcement overshadowed the earnings beat, with reports noting a sharp market sell-off after the plan was announced. Investors may be concerned about the value and performance of the standalone businesses, as well as how the separation will be structured. CVS Health drops on breakup plan

About CVS Health

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.